IP Library Patent Application 15615829
Patent Application
App. No. 15/615,829

SYSTEM AND METHOD ENHANCED CANNABINIOD EFFECT DELIVERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/615,829
Abstract

A class of medically-effective formulations comprising cannabinoids, and terpenes, using β-myrcene to improve effectiveness. B-myrcene decreases resistance across the blood-brain barrier for both itself and a plurality of other medically-active compounds such as other terpenes, cannabinoids, and flavonoids. Further, β-myrcene has been determined to raise the saturation level of the cannabinoid receptor CB1 for phytocannabinoids such as delta(9)-tetrahydrocannabinol, and to increase cell membrane permeability for itself as well as cannabinoids, terpenes, flavonoids and other naturally occurring cannabis compounds, thereby improving therapeutic benefits of cannbis formulations.

Claims (12)

1 . A formulation for rapid therapeutic appetite enhancement for cancer patients, comprising:

an oil extracted from one or more strains of cannabis by use of at least one of: high pressure flash chromatography, fractional distillation, steam distillation, supercritical fluid extraction, and solvent extraction; and

at least 1% by weight purified β-myrcene added after oil extraction to increase speed of uptake and of saturation level of appetite-enhancing cannabinoids;

wherein the extracted oil comprises a plurality of cannabinoids, a plurality of terpenes, and a plurality of flavonoids;

wherein the appetite-enhancing cannabinoids comprise at least δ-9-tetrahydrocannabinol.

2 . The formulation of claim 1 , comprising at least one purified cannabinoid.

3 . The formulation of claim 2 wherein the purified cannabinoid is chosen from a set comprising delta(9)-tetrahydrocannabinol, cannabidiol, cannabichromene, cannabinol, cannabigerol, tetrahydrocannabivarin, cannabidivarin, δ-8-tetrahydrocannabinol, delta(9)-tetrahydrocannabinolic acid, and cannabidiolic acid.

4 . The formulation of claim 1 , comprising at least one purified terpene.

5 . The formulation of claim 4 , wherein the purified terpene is chosen from a set comprising β-myrcene, αα-pinene, ocimene, terpineol, β-caryophyllene, linalool, limonene, terpinolene, valencene, and geraniol.

6 . The formulation of claim 4 , wherein the purified terpene is chosen from a set comprising phellandrene, carene, terpinene, fenchol, borneol, bisabolol, phytol, camphene, sabinene, camphor, isoborneol, menthol, cedrene, nerolidol, guaiol, isopulegol, geranyl, cymene, eucalyptol and pulegone.

7 . The formulation of claim 1 comprising at least one purified flavonoid.

8 . The formulation of claim 7 , wherein the purified flavonoid is chosen from a set comprising phenolic acids, stilbenoids, phytochemicals, dihydroflavonols, anthocyanins, anthocyanidins, polyphenols, tannins, flavones, flavonols, flavan-3-ols, flavan-4-ol, flavan-3,4-diol, antioxidants, and homoisoflavonoids, phenylpropanoids, phloroglucinols, coumarins, phenolic acids, naphthodianthrones, steroid glycosides, bioflavonoids, and isoflavonoids.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTION TO THE CONVEYING PARTY ON COVER SHEET PREVIOUSLY RECORDED AT REEL: 047468 FRAME: 0759. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 23, 2018
From: NC3 SYSTEMS
To: CMG PARTNERS, INC.
Reel/Frame 047857/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2018
From: GALVIN, BRIAN R.
To: CMG PARTNERS, INC.
Reel/Frame 047468/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2017
From: THACKER, LARRY NELSON; THANG VU, MICHAEL VIET; FORCE, ROBERT DANIEL; THACKER, ALEXANDER NELSON; ADAMS, AARON NICHOLAS
To: NC3 SYSTEMS
Reel/Frame 043864/0129 →